If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Pfizer unveils CEO succession plan

Current COO Albert Bourla will take over for Ian Read on Jan. 1

by Lisa M. Jarvis
October 3, 2018 | A version of this story appeared in Volume 96, Issue 40

In an expected transition, Pfizer’s chief operating officer, Albert Bourla, will take over as CEO from Ian Read when Read steps down at the end of the year.

A headshot of outgoing Pfizer CEO Ian Read.
Credit: Pfizer
Ian Read will retire at the end of the year.
A headshot of incoming Pfizer CEO Albert Bourla.
Credit: Pfizer
Albert Bourla will take over as Pfizer's CEO on Jan. 1, 2019.

Read came to Pfizer in 1978 after getting his accounting degree and never left. When he became CEO in late 2010, his immediate challenge was to help the pharma behemoth navigate a period of patent losses on its drugs, including its top seller, the cholesterol-lowering pill Lipitor. During his first year at the helm, Read made deep cuts to the company’s research organization. He later spun out its animal health business into a standalone unit, Zoetis.

A longtime critic of the U.S. corporate tax system, Read made two failed bids for smaller drug companies that would have allowed Pfizer to shift its headquarters to countries with more favorable tax laws. The first attempt at a so-called reverse merger was in 2014, for Britain’s AstraZeneca, which rebuffed Pfizer’s $119 billion offer. A year later, Pfizer unveiled a $160 billion deal to acquire Allergan, which is based in Ireland, but backed out when the U.S. government made it more difficult to realize tax savings from the deal.

Bourla also has decades of experience at Pfizer: He started in 1993 as a technical director in Greece, and ascended through the ranks to his current position as COO. Like Read in 2010, Bourla will be contending with looming generic competition on a critical product—this time, the pain treatment Lyrica. He officially takes the reins on Jan. 1, 2019.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.